Catatan sumber primer
PenentuPermohonan diajukan
Beam Therapeutics berencana mengajukan BLA risto-cel paling cepat akhir tahun 2026
8-K mengonfirmasi bahwa perusahaan mengharapkan untuk mengajukan BLA AS untuk risto-cel pada penyakit sel sabit paling cepat Desember 2026, didukung oleh fasilitas kredit non-dilutif baru senilai $500 juta dengan Sixth Street yang memperpanjang runway kas hingga pertengahan 2029 dan mendanai peluncuran komersial yang diantisipasi.
Fakta utama
- Diajukan
- 24 Feb 2026, 12.05
- Peristiwa
- Permohonan diajukan
- Arah
- Positif
- Perusahaan
BEAMBeam Therapeutics- Aset
- risto-cel
- Sumber
- SEC 8-K
- Keyakinan
- Bersumber
- Masa ketahanan kas
- Pertengahan 2029
- Penarikan minimum
- $200 juta
- Fasilitas kredit tunai
- $500 juta
Kutipan sumber
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Ca